Compare Sanofi SA (SNY) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Williams Companies Inc — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Williams Companies Inc trades at $73.83 (market cap $88.45B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| SNY | WMB | |
|---|---|---|
Market Cap | $104.30B | $88.45B |
Sector | Health | Energy |
52-Week High | $52.34 | $79.40 |
52-Week Low | $41.33 | $56.51 |
Enterprise Value | $124.19B | $119.07B |
Dividend Yield | 5.55% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Williams Companies (WMB) trades at $73.60, up 2.44% with a bullish technical signal despite mixed earnings history. The company reported strong Q1 2026 results but missed Q2 estimates, while raising full-year EBITDA guidance to $8.4 billion. Analyst consensus remains strongly bullish with a $87.14 price target, supported by the recent $5.5 billion Momentum Midstream acquisition that enhances Gulf Coast exposure and supports 11% annual growth targets through 2030.
WMB presents a compelling investment case with strong profitability metrics (25.18% net margin, 24.02% ROE) and dividend stability ($2.10 annualized). Key risks include execution challenges from the Momentum integration, debt levels at 52.07% of assets, and potential volatility from energy market fluctuations. The stock offers 18% upside to consensus target with institutional support despite recent position reductions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
